A two-step radiolabelling protocol of a cancer relevant cRGD peptide is described where the fluorinase enzyme is used to catalyse a transhalogenation reaction to generate [ 
. The enzyme will also catalyse a transhalogenation reaction when 5 0 -chloro-5 0 -deoxyadenosine (ClDA, 4) is presented as a substrate with L-selenomethionine (SeMet) and fluoride. 4 In this case a reverse reaction occurs where SeMet attacks ClDA 4 and generates selenoSAM (SeSAM, 5) in situ, after which the fluoride ion, the favoured nucleophile, reacts with SeSAM 5 to generate FDA 2 (Scheme 1B). Positron emission tomography (PET) has emerged as indispensable functional imaging modality, complementary to anatomical imaging modalities such as magnetic resonance imaging (MRI) and computerised tomography (CT). 5 The development of new methodologies for labelling molecules with positron emitting isotopes (such as carbon-11 and fluorine-18) continues to receive widespread attention, especially for labelling biomolecules. The fluorinase enzyme functions best in buffer (pH 7.8, 37 1C) under ambient conditions and may present some additional advantages over current methods for this reason. We have recently demonstrated that the C-2 position of the substrate can be substituted with acetylene and this modified substrate, 2-ethynyl-ClDA (ClDEA, 6), is processed to 2-ethynyl-FDA (FDEA, 8) (B60% rate compared to ClDA). 13 This led to the demonstration of a 'last step' labelling protocol of a cRGD peptide by extending a tetraethyleneglycol (TEG) chain from the acetylene moiety at C-2 of ClDEA 6 to a cRGD motif to give ClDEA-TEG-RGD 9, which allowed for the last step fluorinase enzyme based transhalogenation and radiolabelling of this peptide construct with fluorine-18 under ambient conditions (Scheme 1B), generating [ We set out to investigate the copper-mediated click reaction under cold conditions, and explore the reaction of both synthetic FDEA (8) , and that produced by fluorinase transhalogenation with an azide bearing RGD peptide 12. Firstly, the fluorinase enzyme catalysed transhalogenation of ClDEA 6 (Fig. 1A) was carried out under our previously reported conditions 13 to give a 78 : 22 mixture of FDEA (8, t R = 8.5 min) and ClDEA (6, t R = 10.5 min) in 2 hours (Fig. 1B) . After heat precipitation and centrifugation to remove the enzyme, the supernatant containing efficiently generate the triazole, FDEA-RGD (13, t R = 12.8 min), in 70 minutes (Fig. 1C) . The click reaction also proceeded efficiently with synthetic ClDEA 6 and FDEA 8 on a preparative (Fig. 2D) .
There is some uncertainty as to the metabolic stability of these C-2 substituted adenosine analogues. If such compounds are metabolised, such that fluoride ion is released, then they become redundant as PET radiotracers because the released [ 18 F]fluoride accumulates in the bone. 15 This issue was addressed satisfactorily in the last step labelling study reported recently, 13 where the radiolabelled product was injected into healthy rats to evaluate defluorination and bone uptake. The radiolabelled product in that study, [ Fig. 3 and Fig. S19 , ESI †). 16 Evaluating the binding of test molecules to immobilised a V b 3 integrin is a standard method of assessing binding affinities of RGD peptides. 17 The affinity of the peptide for a V b 3 is measured as IC 50 , but normalized to the IC 50 of a reference peptide (GRGDSPK) to allow inter-assay comparisons. The normalized affinity, ''Q'', is defined as IC 50 (peptide)/IC 50 (GRGDSPK) by Haubner et al. as c(RGDfV) whose Q factor has been reported to be 0.033. 19 These data show that the fluorodeoxyadenosine moiety does not significantly perturb the binding of the cRGD motif to a V b 3 integrin.
In conclusion, we demonstrate a straightforward twostep radiolabelling protocol for cRGD peptides. This method complements our recently disclosed 'last step' radiolabelling protocol and despite the extra step, it has some advantage in that the enzyme substrate, ClDEA 6, is more readily prepared synthetically. Normally fluorine-18 labelling protocols require 19 and measured in an identical assay.
